Keyphrases
Homologous Recombination Deficiency
100%
PARP Inhibitor (PARPi)
54%
Ovarian Cancer
37%
Inhibitor Sensitivity
33%
Laboratory-developed Test
33%
Mutational Signatures
33%
RAD51
33%
Advanced Ovarian Cancer
33%
Genetic Variants
33%
PARP Inhibitor Sensitivity
33%
HR Deficiency
29%
Progression-free Survival
21%
HRDetect
20%
Deficiency Score
12%
Sequence Data
12%
ENGOT
10%
Clinical Benefit
10%
BRCA1, BRCA2
8%
Cancer Genome Atlas
8%
Chromosome Rearrangement
8%
Genetic Aberrations
8%
Cancer-specific
8%
Whole Exome Sequencing
8%
Homologous Recombination Deficiency Score
8%
Inhibitor Response
7%
RAD51 Foci
7%
Open Standards
7%
Tumor
7%
Exon 11
6%
Breast Cancer Susceptibility Gene 1 (BRCA1)
6%
Medicine and Dentistry
Homologous Recombination
100%
Ovarian Cancer
66%
PARP Inhibitor
45%
Tumor Biopsy
37%
Diagnosis
33%
Malignant Neoplasm
33%
Neoplasm
20%
BRCA1
15%
Progression Free Survival
10%
Krukenberg Tumor
10%
The Cancer Genome Atlas
8%
Exome Sequencing
8%
Breast Cancer
8%
Biological Marker
6%
Biopsy Technique
6%
Clinical Trial
6%
Exon
6%
Biochemistry, Genetics and Molecular Biology
Homologous Recombination
100%
Poly ADP Ribose Polymerase
66%
BRCA1
40%
Exome Sequencing
33%
Poly ADP Ribose Polymerase
33%
RAD51
33%
Genetic Divergence
33%
Progression Free Survival
22%
Long Term Survival
16%
Wild Type
16%
Exon
6%
